index - Epidemiology in dermatology and evaluation of therapeutics Accéder directement au contenu

DOCUMENTS

79

 

NOTICES

153

 

 

MOTS CLES

Atrial fibrillation Stability Case-Control Studies Biomédicaments Sipuleucel-T Addiction Placebo Pharmacovigilance Treatment CTLA-4 Accelerometer Apre-milast Burden Ethics Anti-HCV Direct Acting Antivirals DAA Prostate cancer Angiotensin receptor blockers Abus d'antibiotiques Azathioprine Immune-related adverse events Biological Therapy Arrhythmia Ankylosing Antimicrobials Etanercept ASDAS Psoriasis Intensive care Sacroiliitis Autoimmune diseases Immunotherapy Biosimilar Pharmaceuticals Vigibase® Anxiety COVID-19 Cardiotoxicity Alitretinoin Infliximab Biologic Ankylosing spondylitis Meta-Analysis ArtThese Antimicrobial resistance Anxiété Biologic drug Auto-immune hepatitis Antimicrobiens Auto-Diagnostic Axial spondyloarthritis Anticancer drugs Amyloidosis Cancer Acute Myeloid Leukaemia AML Antibiotic misuse Adverse side effects Access to care Glucocorticoids Apremilast Bacterial rhinosinusitis Calcium channel blockers Drug reaction Management Angiotensin-converting enzyme inhibitors Aging Cardiovascular therapy Albinism Care pathway Epidemiology Atopic dermatitis Méta-Analyse Antibiotics Ustekinumab Psoriatic arthritis Endocrine toxicity Biological therapy Graft-versus-host disease Dermatology Anti-TNF Beta-lactam antibiotics Adalimumab Drug survival Autoimmunity Cardiomyopathy Quality of life Spondyloarthritis Antibiotic resistance Alcohol Pharmacoepidemiology BTK protein Biologics Biologic therapy Cattle Cardio-oncology CSK tyrosine-protein kinase Immune checkpoint inhibitors Primary adrenal insufficiency Cardiovascular risk Biomarkers Adolescent Arthritis

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS